401 Professional Drive
United States - Map
|Full Time Employees:||27|
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company develops lead product GMI-1070, a glycomimetic drug candidate that has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. It also develops GMI-1271, a specific E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers; and GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Gaithersburg, Maryland.
|Mrs. Rachel K. King ,
Founder, Chief Exec. Officer and Director
|Mr. Brian M. Hahn ,
Chief Financial Officer
|Dr. John L. Magnani Ph.D.,
Chief Scientific Officer, VP and Director
|Dr. Helen M. Thackray M.D., FAAP,
Chief Medical Officer and VP of Clinical Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|